Press Releases
Andrew Hufford Hosts Federalist Society Teleforum Following SCOTUS Arguments in Amgen v. Sandoz
April 26, 2017

SALT LAKE CITY—Andrew A. Hufford, an Intellectual Property Attorney with Brinks Gilson & Lione, hosted a live Courthouse Steps teleforum on behalf of the Intellectual Property Practice Group of The Federalist Society for Law & Public Policy on April 26, 2017.

Mr. Hufford presented the teleforum after attending the U.S. Supreme Court oral argument in the Amgen Inc. v. Sandoz Inc. case. This landmark case is the first concerning the Biologics Price Competition and Innovation Act to reach the high court, and addresses questions of statutory interpretation of the 2010 law that created an abbreviated pathway for FDA approval of biologic therapeutics determined to be “biosimilar” to a reference biological product.

A trained biochemist, Hufford focuses his practice on U.S. and global patent drafting and prosecution for technologies related to biotechnology, pharmaceuticals, chemicals, and medical devices. He also has significant experience in patent and trade secret litigation, inter partes review, and patent due diligence.

Mr. Hufford is the current Vice Chair of the Utah State Bar Intellectual Property Section, a founding member of the David K. Winder IP Inn of Court, and an active member of the American Bar Association’s IP Law Section.

For information about The Federalist Society, see

For more information and to listen to a podcast of the April 26 Courthouse Steps teleforum, visit

Brinks Gilson & Lione

Celebrating its centennial year in 2017, Brinks Gilson & Lione is one of the largest intellectual property law firms in the US, and helps clients around the world to protect and enforce their intellectual property rights. Brinks Gilson & Lione’s more than 140 lawyers, patent agents and scientific advisors assist clients in all aspects of patent, trademark, unfair competition, trade secret, and copyright law. Brinks attorneys provide informed counsel with respect to innovations in a range of complex and valuable technologies, including pharmaceuticals, chemicals, bioengineering, industrial manufacturing, electronics and software, and medical devices. More information is at

Forward Thinkers